Sun Pharma Advanced Research Co. Ltd. released its earnings results on Nov 10, 2025. The company reported -₹2.337 earnings per share for the quarter, missing the consensus estimate of N/A by -₹2.337.

Is Sun Pharma Advanced Research Co. Ltd. overvalued?

According to Wall Street analysts Sun Pharma Advanced Research Co. Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sun Pharma Advanced Research Co. Ltd. pay dividends?

Sun Pharma Advanced Research Co. Ltd. does not currently pay dividends.

What is Sun Pharma Advanced Research Co. Ltd.’s EPS estimate?

Sun Pharma Advanced Research Co. Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sun Pharma Advanced Research Co. Ltd. have?

Sun Pharma Advanced Research Co. Ltd. has 324,521,580 shares outstanding.

What happened to Sun Pharma Advanced Research Co. Ltd.’s price movement after its last earnings report?

Sun Pharma Advanced Research Co. Ltd. reported an EPS of -₹2.337 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.388%.

Which hedge fund is a major shareholder of Sun Pharma Advanced Research Co. Ltd.?

Currently, no hedge funds are holding shares in IN:SPARC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sun Pharma Advanced Research Co. Ltd.

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited